key: cord-0939915-8xfvh9p7
authors: Motta, Ilaria; Centis, Rosella; D’Ambrosio, Lia; García-García, José-María; Goletti, Delia; Gualano, Gina; Lipani, Filippo; Palmieri, Fabrizio; Sánchez-Montalvá, Adrián; Pontali, Emanuele; Sotgiu, Giovanni; Spanevello, Antonio; Stochino, Claudia; Tabernero, Eva; Tadolini, Marina; van den Boom, Martin; Villa, Simone; Visca, Dina; Migliori, Giovanni Battista
title: Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts
date: 2020-05-14
journal: Pulmonology
DOI: 10.1016/j.pulmoe.2020.05.002
sha: b184a422008c432725f2cd6c97353d4fefc0a164
doc_id: 939915
cord_uid: 8xfvh9p7

Abstract Little is known about the relationship between the COVID-19 and tuberculosis (TB). The aim of this study is to describe a group of patients who died with TB (active disease or sequelae) and COVID-19 in two cohorts. Data from 49 consecutive cases in 8 countries (cohort A) and 20 hospitalized patients with TB and COVID-19 (cohort B) were analysed and patients who died were described. Demographic and clinical variables were retrospectively collected, including co-morbidities and risk factors for TB and COVID-19 mortality. Overall, 8 out of 69 (11.6%) patients died, 7 from cohort A (14.3%) and one from cohort B (5%). Out of 69 patients 43 were migrants, 26/49 (53.1%) in cohort A and 17/20 (85.0%) in cohort B. Migrants: 1) were younger than natives; in cohort A the median (IQR) age was 40 (27-49) VS. 66 (46-70) years, whereas in cohort B 37 (27-46) VS. 48 (47-60) years; 2) had a lower mortality rate than natives (1/43, 2.3% versus 7/26, 26.9%; p-value: 0.002); 3) had fewer co-morbidities than natives (23/43, 53.5 % versus 5/26- 19.2%) natives; p-value: 0.005). The study findings show that: 1) mortality is likely to occur in elderly patients with co-morbidities; 2) TB might not be a major determinant of mortality and 3) migrants had lower mortality, probably because of their younger age and lower number of co-morbidities. However, in settings where advanced forms of TB frequently occur and are caused by drug-resistant strains of M. tuberculosis, higher mortality rates can be expected in young individuals.

s World Health Organization Regional office for Europe, Copenhagen, Denmark 53 Little is known about the relationship between the COVID-19 and tuberculosis (TB). The aim of 54 this study is to describe a group of patients who died with TB (active disease or sequelae) and 55 COVID-19 in two cohorts. 56 Data from 49 consecutive cases in 8 countries (cohort A) and 20 hospitalized patients with TB and 57 COVID-19 (cohort B) were analysed and patients who died were described. Demographic and 58 clinical variables were retrospectively collected, including co-morbidities and risk factors for TB 59 and COVID-19 mortality. 60 Overall, 8 out of 69 (11.6%) patients died, 7 from cohort A (14.3%) and one from cohort B (5%). 61 Out of 69 patients 43 were migrants, 26/49 (53.1%) in cohort A and 17/20 (85.0%) in cohort B. The study findings show that: 1) mortality is likely to occur in elderly patients with co-morbidities; 67 2) TB might not be a major determinant of mortality and 3) migrants had lower mortality, probably 68 because of their younger age and lower number of co-morbidities. However, in settings where 69 advanced forms of TB frequently occur and are caused by drug-resistant strains of M. tuberculosis, 70 higher mortality rates can be expected in young individuals.

The COVID-19 pandemic caused by the SARS-CoV-2 (severe acute respiratory syndrome 76 coronavirus 2) is causing a debate on preventive, diagnostic, and therapeutic strategies among 77 scientists, clinicians, and public health experts [1] [2] [3] . 78 The current scientific evidence suggests that individuals with the disease are infectious, SARS-79 CoV-2 rapidly spreads within the community because of the lack of herd immunity 4,5 , it has high 80 case-fatality rate among elderly and patients with co-morbidities and can stretch unprepared 81 healthcare systems causing rapid collapse of intensive care units (ICU) 1-3,6 .

Patients with COVID-19 may complain of cough, fever, tiredness, dyspnoea, and other signs and The aim of this study is to describe for the first time a group of patients who died with TB (active 89 disease or sequelae) and COVID-19 in the cohorts A and B. All consecutive cases with a diagnosis of TB (at any time in the past, so as to include patients with 101 TB sequelae, which may be a risk factor for mortality) and COVID-19 from cohorts A and B were 102 included.

J o u r n a l P r e -p r o o f TB patients were microbiologically confirmed (Table 1) , whereas SARS-CoV-2 infection was 106 confirmed by molecular biology. The first COVID-19 diagnosis was made on March 12 th , 2020; 107 data were updated as of May 5 th , 2020.

Continuous variables, if not otherwise specified, are presented as medians (IQR-Interquartile 109 ranges). Categorical variables were described with absolute and relative (percentage) frequencies.

Chi-squared and Fisher exact tests were used to compare qualitative variables when appropriate. A 111 two-tailed p-value less than 0.05 was considered statistically significant.

The MuLBSTA (multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking 113 history, hypertension, and age) clinical score used to predict 90-day mortality due to viral To the best of our knowledge this is the first report of patients dying with TB and COVID-19, 150 including 69 patients from the two largest cohorts of co-infected patients available so far.

Although the case-fatality rate was rather high (overall 10.6%, but 14.3% in the first cohort) and 152 still preliminary (it can increase over time within both cohorts), the results seem consistent with 153 those observed in other cohorts of COVID-19 patients 1-3 . In general, all patients (except one) were 154 aged >65 years, and were affected by >2 co-morbidities.

In all cases COVID-19 contributed to worsen the prognosis of TB patients and/or to cause death. 

The MuLBSTA score has been developed for viral pneumonia 11 and has similar inputs to risk 162 factors for mortality seen in the initial COVID-19 patient cohorts in China 12 . Age has a much 163 stronger odds ratio for increasing mortality in COVID-19 patients than in other viral pneumonia 164 patients. A score higher than 12 points is considered high risk (bacterial coinfection detected by 165 sputum or culture -as for concomitant active TB counts 4 points.) In our patients it does not seem to 166 predict mortality well: the median value is 10 and only 2 patients scored values higher than 12.

TB and COVID-19 seem to absorb relevant human and economic resources, although the relatively 168 small size of the cohort prevents drawing specific conclusions.

The main limitation of this preliminary study is that the cohort, although likely to report the vast 

The study findings show that: 1) mortality is likely to occur in elderly patients with co-morbidities; 173 2) TB might not be a major determinant of mortality and 3) migrants had lower mortality, probably 174 because of their younger age and lower number of co-morbidities. However, in settings where 175 advanced forms of TB frequently occur and are caused by drug-resistant strains of M. tuberculosis, 176 higher mortality rates can be expected in young individuals.

However, as the study will continue prospectively with the inclusion of GTN countries where TB 178 and COVID-19 patients have not been diagnosed until now, we wish to invite all interested 179 clinicians and programmes to contact us and participate in the study. The following clinicians participate in the project: 

Coronavirus Disease 2019 in China

Clinical findings in a group of 210 patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: 211 retrospective case series

Clinical course and risk factors for mortality 213 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Let us not forget the mask in our attempts to stall the 216 spread of COVID-19

Universal use of face masks for success 219 against COVID-19: evidence and implications for prevention policies

Early consensus management for non-ICU ARF 222

SARS-CoV-2 emergency in Italy: from ward to trenches

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global 229 report

Multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hyper-234 tension and age (MULBSTA) score

Epidemiological and clinical 240 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 241 descriptive study